Ensifentrine
APICAS: 298680-25-8
Sample Stock:
Ensifentrine is a groundbreaking, first-in-class treatment for COPD. Uniquely targeting both the PDE3 and PDE4 pathways, it works by simultaneously opening airways (bronchodilation) and reducing lung inflammation with a single inhaled medicine. Approved by the FDA in June 2024, it is delivered directly to the lungs for targeted relief in adults with chronic obstructive pulmonary disease.
Related Information
Purity:99%+
Registration:GMP/DMF
Biological Profile
Biological Targets
PDE3A·PDE3B·PDE4A·PDE4D·PDE4B·
Associated Conditions
COVID-19·cystic fibrosis·chronic obstructive pulmonary disease·asthma
Key Intermediates
2 Items| Structure | Name | CAS No. | Sample Stock | MDL No. | Details |
|---|---|---|---|---|---|
 | Ensifentrine impurity 6 | 298680-38-3 | - | ||
![9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)3-(2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one structure](https://static.dempochem.com/structures-bw/6953ced48e2037a871373147.svg) | 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)3-(2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one | 298680-39-4 | - |